Bristol-Myers Squibb Breaks Oral Hep C Treatment Barrier
This article was originally published in The Pink Sheet Daily
Executive Summary
The proof-of-concept news is based on the finding that four of 11 patients (36%) in the all-oral arm of an exploratory 21-patient trial achieved a sustained virologic response 12 weeks after completion of treatment, though in the other arm, which added peginterferon and ribavirin to the duo, all 10 patients reached that cure threshold.
You may also be interested in...
High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.